These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20671227)

  • 1. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.
    Orskov B; Rømming Sørensen V; Feldt-Rasmussen B; Strandgaard S
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):2034-9. PubMed ID: 20671227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.
    Reule S; Sexton DJ; Solid CA; Chen SC; Collins AJ; Foley RN
    Am J Kidney Dis; 2014 Oct; 64(4):592-9. PubMed ID: 25134777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.
    Spithoven EM; Kramer A; Meijer E; Orskov B; Wanner C; Abad JM; Aresté N; de la Torre RA; Caskey F; Couchoud C; Finne P; Heaf J; Hoitsma A; de Meester J; Pascual J; Postorino M; Ravani P; Zurriaga O; Jager KJ; Gansevoort RT; ; ;
    Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4(Suppl 4):iv15-25. PubMed ID: 25165182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?
    Jankowska M; Qureshi AR; Barany P; Heimburger O; Stenvinkel P; Lindholm B
    Nephrology (Carlton); 2018 Jan; 23(1):31-36. PubMed ID: 27653449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.
    Hruskova Z; Pippias M; Stel VS; Abad-Díez JM; Benítez Sánchez M; Caskey FJ; Collart F; De Meester J; Finne P; Heaf JG; Magaz A; Palsson R; Reisæter AV; Salama AD; Segelmark M; Traynor JP; Massy ZA; Jager KJ; Tesar V
    Am J Kidney Dis; 2019 Feb; 73(2):184-193. PubMed ID: 30122544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease.
    Orskov B; Sørensen VR; Feldt-Rasmussen B; Strandgaard S
    Nephrol Dial Transplant; 2012 Apr; 27(4):1607-13. PubMed ID: 21873624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.
    Cornec-Le Gall E; Audrézet MP; Rousseau A; Hourmant M; Renaudineau E; Charasse C; Morin MP; Moal MC; Dantal J; Wehbe B; Perrichot R; Frouget T; Vigneau C; Potier J; Jousset P; Guillodo MP; Siohan P; Terki N; Sawadogo T; Legrand D; Menoyo-Calonge V; Benarbia S; Besnier D; Longuet H; Férec C; Le Meur Y
    J Am Soc Nephrol; 2016 Mar; 27(3):942-51. PubMed ID: 26150605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in age at ESRD in autosomal dominant polycystic kidney disease.
    Reed BY; McFann K; Bekheirnia MR; Nobakhthaghighi N; Masoumi A; Johnson AM; Shamshirsaz AA; Kelleher CL; Schrier RW
    Am J Kidney Dis; 2008 Feb; 51(2):173-83. PubMed ID: 18215695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease.
    Orskov B; Christensen KB; Feldt-Rasmussen B; Strandgaard S
    Kidney Int; 2012 May; 81(9):919-24. PubMed ID: 22297678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study.
    Haynes R; Kheradmand F; Winearls CG
    Nephron Clin Pract; 2012; 120(1):c42-7. PubMed ID: 22205054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical burden of autosomal dominant polycystic kidney disease.
    Hung PH; Lin CH; Hung KY; Muo CH; Chung MC; Chang CH; Chung CJ
    Aging (Albany NY); 2020 Feb; 12(4):3899-3910. PubMed ID: 32096480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
    Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
    Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality risk in patients with autosomal dominant polycystic kidney disease.
    Mladsi D; Zhou X; Mader G; Sanon M; Wang J; Barnett C; Willey C; Seliger S
    BMC Nephrol; 2024 Feb; 25(1):56. PubMed ID: 38365638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease.
    Yoo DJ; Agodoa L; Yuan CM; Abbott KC; Nee R
    BMC Nephrol; 2014 Feb; 15():39. PubMed ID: 24571546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable graft survival in renal transplant recipients with polycystic kidney disease.
    Johnston O; O'Kelly P; Donohue J; Walshe JJ; Little DM; Hickey D; Conlon PJ
    Ren Fail; 2005; 27(3):309-14. PubMed ID: 15957548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL; Cadnapaphornchai MA; Chonchol MB; Schrier RW; Gitomer B
    Am J Nephrol; 2016; 44(3):171-8. PubMed ID: 27548646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure.
    Shaw C; Simms RJ; Pitcher D; Sandford R
    Nephrol Dial Transplant; 2014 Oct; 29(10):1910-8. PubMed ID: 24737444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients with autosomal-dominant polycystic kidney disease on peritoneal dialysis: A meta-analysis.
    Boonpheng B; Thongprayoon C; Wijarnpreecha K; Medaura J; Chebib FT; Cheungpasitporn W
    Nephrology (Carlton); 2019 Jun; 24(6):638-646. PubMed ID: 29952039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.
    McKenzie KA; El Ters M; Torres VE; Harris PC; Chapman AB; Mrug M; Rahbari-Oskoui FF; Bae KT; Landsittel DP; Bennett WM; Yu ASL; Mahnken JD
    BMC Nephrol; 2018 Dec; 19(1):378. PubMed ID: 30591038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.